Intravenous Lidocaine in Chronic Neuropathic Pain: A Systematic Review.

Autor:	Lee JH; Departments of Anesthesiology., Koutalianos EP; Department of Physical Medicine and Rehabilitation, SUNY Upstate Medical University, Syracuse, NY., Leimer EM; Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR., Bhullar RK; Departments of Anesthesiology., Argoff CE; Neurology, Albany Medical College, Albany.
Jazyk:	angličtina
Zdroj:	The Clinical journal of pain [Clin J Pain] 2022 Dec 01; Vol. 38 (12), pp. 739-748. Date of Electronic Publication: 2022 Dec 01.
DOI:	10.1097/AJP.0000000000001080
Abstrakt:	Objectives: A systematic review of original research articles was conducted to evaluate the safety and efficacy of lidocaine infusion in the treatment of adult patients with chronic neuropathic pain. Materials and Methods: Original research from 1970 to September 2021 describing adult patients with chronic neuropathic pain receiving at least 1 dose of intravenous lidocaine was included. Extracted data included study design, sample size, patient demographics and comorbidities, etiology and duration of pain, pain intensity scores, time to pain resolution, lidocaine dose and administration frequency, lidocaine serum concentration, and adverse events. Each study was evaluated for level of evidence using the 2017 American Association of Neurology classification system. Results: Twenty-seven studies evaluating lidocaine infusion treatment in chronic neuropathic pain met inclusion criteria. One class I study was identified for patients with neuropathic pain due to spinal cord injury . Two Class II studies were identified, one describing neuropathic pain due to peripheral nerve injury and another due to diabetic neuropathy. Across all studies, study design, participants, and experimental interventions were heterogenous with wide variation. Discussion: This qualitative review found insufficient, heterogenous evidence and therefore no recommendation can be made for lidocaine infusion treatment in patients with chronic neuropathic pain due to spinal cord injury, peripheral nerve injury, diabetic neuropathy, postherpetic neuralgia, or complex regional pain syndrome type II. Larger randomized, double-blind, placebo-controlled studies are required to further establish the efficacy of lidocaine infusion in patients with these etiologies of chronic neuropathic pain. Competing Interests: C.E.A. has served as a consultant to Neumentum (Summit, NJ), X Gene Pharma (Shanghai, China), Enzen Therapeutics (San Diego, CA), Seelos (New York, NY), Vertex (Boston, MA), RedHill Pharma (Tel-Aviv, Israel), AppliedVR (Van Nuys, CA), and SPR Therapeutics (Cleveland, OH), Nevro (Redwood City, CA), and is a member of the speaker’s bureau for Amgen (Thousand Oaks, CA), AbbVie (North Chicago, IL), Biohaven (New Haven, CT), Lilly (Indianapolis, IN), Averitas (Morristown. NJ), RedHill Pharma (Tel-Aviv, Israel), and Teva (Tel-Aviv, Israel). The remaining authors declare no conflict of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu